{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:23Z","timestamp":1793726003463,"version":"4.6.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002655","name":"Terry Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010476","name":"Tata Memorial Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ijrobp.2024.03.023","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:38:09Z","timestamp":1711643889000},"page":"537-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial"],"prefix":"10.1016","volume":"120","author":[{"given":"Priyamvada","family":"Maitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guncha","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyita","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Phurailatpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vysakh","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.03.023_bib0001","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0002","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. part I: Intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high-risk prostate cancer (POP-RT): A randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5301\/tj.5000681","article-title":"Understanding urinary toxicity after radiotherapy for prostate cancer: First steps forward","volume":"103","author":"Rancati","year":"2017","journal-title":"Tumori J"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2016.01.013","article-title":"Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy","volume":"119","author":"Thor","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0006","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(22)00544-7","article-title":"Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy","volume":"23","author":"Martin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0007","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature","volume":"61","author":"Bud\u00e4us","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0008","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.06.011","article-title":"Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial","volume":"116","author":"Yahya","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0009","article-title":"Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity and mitigation strategies","volume":"45","author":"Huck","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0011","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0012","first-page":"31","article-title":"Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice","volume":"6","author":"Inokuchi","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0013","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0014","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jjco\/hyt028","article-title":"Evaluation of interobserver and interscale agreement in assessing late bowel toxicity after pelvic radiation in patients with carcinoma of the cervix","volume":"43","author":"Chinnachamy","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0015","first-page":"2015","article-title":"Comparison of Common Terminology Criteria for Adverse Events v3.0 and Radiation Therapy Oncology Group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer","volume":"34","author":"Yoshida","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0016","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clon.2019.05.020","article-title":"Prostate radiotherapy in India: Evolution, practice and challenges in the 21st century","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0018","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/S0167-8140(23)08750-9","article-title":"OC-0924 Prostate RT In high risk or N+ Moderate versus Extreme hypofractionation (PRIME): An interim analysis","volume":"182","author":"Murthy","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.03.023_bib0019","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624004395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624004395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T10:21:55Z","timestamp":1738146115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624004395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0360301624004395"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.023","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}